Logo

Sage and Biogen Report Results of Zuranolone in P-III WATERFALL Study for Major Depressive Disorder

Share this

Sage and Biogen Report Results of Zuranolone in P-III WATERFALL Study for Major Depressive Disorder

Shots:

  • The P-III WATERFALL study involves assessing the efficacy and safety of zuranolone (50mg- once-nightly for 2wks.) in 543 adults aged 18-64yrs. with MDD with a HAMD-17 total score ≥24 at screening and day 1 prior to dosing
  • The study met its 1EPs demonstrating improvement in depressive symptoms @day15 as assessed by the HAMD-17 total score (-14.1 vs -12.3); mean SD baseline HAMD-17 score at entry into the study (26.8 vs 26.9); TEAEs (60.1% vs 44.6%)
  • Zuranolone is an investigational oral NAS GABA-A receptor PAM and has received BTD from the US FDA. The therapy is currently being evaluated as a potential rapid-acting- 2wks. treatment for PPD and MDD in the NEST and LANDSCAPE studies

Ref: Business Wire | Image:Biogen

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions